REG - Celadon Pharma. PLC - Successful Completion of Eighth Harvest of 2024

Celadon PharmaceuticalsAnnouncement

16/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240716:nRSP4929Wa&default-theme=true

RNS Number : 4929W  Celadon Pharmaceuticals PLC  16 July 2024

 

Celadon Pharmaceuticals Plc

 

("Celadon", the "Group" or the "Company")

 

Successful completion of eighth harvest of 2024

 

On track for fifteen harvest year

 

London, 16 July 2024 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the development, production and sale of
breakthrough cannabis-based medicines, is pleased to announce the successful
completion of its eighth harvest of 2024.

 

Celadon's innovative indoor facility, which utilises modular hydroponic
technology, comprises three sets of flowering rooms in each phase. The Group's
ability to control the plants' growing environment means that it expects to
produce 15 harvests per year - with five harvests per year from each set of
rooms. The successful completion of the eighth harvest demonstrates that the
Group is on course to complete the forecasted 15 harvests this calendar year.

 

The yields obtained from the harvests are also increasing in line with
management's expectations as the cultivation environment is adjusted to the
different strains' individual characteristics. Additional yield enhancement
developments are in process and are anticipated to further improve yields, in
line with Celadon's commitment to continuous improvement.

 

The product produced from these harvests is being supplied to the two UK
Pharmaceutical companies with which the Group entered sales contracts, as
announced on 24 May and 5 September 2023. These contracts are anticipated to
generate revenue of up to £1.4 million per annum. The amount of suppliable
product from the first harvests has reduced slightly because some of it will
undergo stability testing to demonstrate its quality even after an extended
period of time.

 

Now that Celadon is in a regular harvesting cycle, with harvests occurring
typically every three weeks, the Group is targeting to provide a stable and
continued supply of high-grade pharmaceutical product, helping to resolve the
current availability issues in the UK, including the delays caused by
importing.

 

James Short, Chief Executive Officer of Celadon Pharmaceuticals, commented:

 

"Just over halfway into 2024, we are pleased to announce the successful
completion of our eighth harvest this year. Based on our success so far, we
remain on track to achieve our forecast of 15 harvests for the year. This
milestone underscores the merit of our modular facility design, which enables
regular harvests and allows us to manage our production costs effectively,
even in the unlikely event of lower-than-anticipated demand. This achievement
not only highlights our capabilities as a trusted provider of
pharmaceutical-grade cannabis but also positions us as a key UK player in
resolving the well-documented supply challenges faced by the UK market."

 

 

Enquiries:

 

 Celadon Pharmaceuticals Plc
 James Short                                               Via Powerscourt

 Jonathan Turner

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts                             +44 (0)20 7523 8000

 Global Investment Strategy UK Limited (Joint Broker)
 Callum Hill                                               +44 (0)20 7048 9400

 Sodali & Co
 Elly Williamson / Sam Austrums / Nick Johnson             +44 (0)20 7250 1446

 

About Celadon Pharmaceuticals Plc

 

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on
the development, production and sale of breakthrough cannabis-based medicines.
Its primary focus is on improving quality of life for chronic pain sufferers,
as well as exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved
and comprises indoor hydroponic cultivation, proprietary GMP extraction and an
analytical and R&D laboratory. Celadon's Home Office licence allows for
the commercial supply of its pharmaceutical-grade cannabis product. The Group
owns an approved clinical trial using cannabis-based medicinal products to
treat chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics, which is developing a licensed
cannabinoid medicine to treat children with Autism Spectrum Disorder.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDGGDRBUBDGSU